ID   ACHA_HUMAN              Reviewed;         482 AA.
AC   P02708; B4DRV6; D3DPE8;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1990, sequence version 2.
DT   07-APR-2021, entry version 224.
DE   RecName: Full=Acetylcholine receptor subunit alpha;
DE   Flags: Precursor;
GN   Name=CHRNA1; Synonyms=ACHRA, CHNRA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6688857; DOI=10.1038/305818a0;
RA   Noda M., Furutani Y., Takahashi H., Toyosato M., Tanabe T., Shimizu S.,
RA   Kikyotani S., Kayano T., Hirose T., Inayama S., Numa S.;
RT   "Cloning and sequence analysis of calf cDNA and human genomic DNA encoding
RT   alpha-subunit precursor of muscle acetylcholine receptor.";
RL   Nature 305:818-823(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3338555; DOI=10.1016/0014-5793(88)81430-3;
RA   Schoepfer R., Luther M., Lindstrom J.M.;
RT   "The human medulloblastoma cell line TE671 expresses a muscle-like
RT   acetylcholine receptor. Cloning of the alpha-subunit cDNA.";
RL   FEBS Lett. 226:235-240(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM 2).
RC   TISSUE=Muscle;
RX   PubMed=1694127; DOI=10.1002/j.1460-2075.1990.tb07378.x;
RA   Beeson D., Morris A., Vincent A., Newsom-Davis J.;
RT   "The human muscle nicotinic acetylcholine receptor alpha-subunit exist as
RT   two isoforms: a novel exon.";
RL   EMBO J. 9:2101-2106(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Thymus;
RX   PubMed=7725386;
RA   Gattenloehner S., Brabletz T., Schultz A., Marx A.,
RA   Mueller-Hermelink H.-K., Kirchner T.;
RT   "Cloning of a cDNA coding for the acetylcholine receptor alpha-subunit from
RT   a thymoma associated with myasthenia gravis.";
RL   Thymus 23:103-113(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   PROTEIN SEQUENCE OF 21-482 (ISOFORM 1).
RX   PubMed=2449458; DOI=10.1172/jci113369;
RA   Hohlfeld R., Toyka K.V., Miner L.L., Walgrave S.L., Conti-Tronconi B.M.;
RT   "Amphipathic segment of the nicotinic receptor alpha subunit contains
RT   epitopes recognized by T lymphocytes in myasthenia gravis.";
RL   J. Clin. Invest. 81:657-660(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 78-113.
RX   PubMed=8441631; DOI=10.1093/nar/21.2.233;
RA   Talib S., Okarma T.B., Lebkowski J.S.;
RT   "Differential expression of human nicotinic acetylcholine receptor alpha
RT   subunit variants in muscle and non-muscle tissues.";
RL   Nucleic Acids Res. 21:233-237(1993).
RN   [9]
RP   SUBUNIT.
RX   PubMed=15609996; DOI=10.1021/bi048918g;
RA   Ellison M., Gao F., Wang H.L., Sine S.M., McIntosh J.M., Olivera B.M.;
RT   "Alpha-conotoxins ImI and ImII target distinct regions of the human alpha7
RT   nicotinic acetylcholine receptor and distinguish human nicotinic receptor
RT   subtypes.";
RL   Biochemistry 43:16019-16026(2004).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF VAL-300.
RX   PubMed=27375219; DOI=10.1002/humu.23043;
RA   Shen X.M., Okuno T., Milone M., Otsuka K., Takahashi K., Komaki H.,
RA   Giles E., Ohno K., Engel A.G.;
RT   "Mutations causing slow-channel myasthenia reveal that a valine ring in the
RT   channel pore of muscle AChR is optimized for stabilizing channel gating.";
RL   Hum. Mutat. 37:1051-1059(2016).
RN   [12]
RP   VARIANT CMS1A SER-198.
RX   PubMed=7619526; DOI=10.1016/0896-6273(95)90080-2;
RA   Sine S.M., Ohno K., Bouzat C., Auerbach A., Milone M., Pruitt J.N. II,
RA   Engel A.G.;
RT   "Mutation of the acetylcholine receptor alpha subunit causes a slow-channel
RT   myasthenic syndrome by enhancing agonist binding affinity.";
RL   Neuron 15:229-239(1995).
RN   [13]
RP   VARIANT CMS1A LYS-262.
RX   PubMed=8872460; DOI=10.1093/hmg/5.9.1217;
RA   Engel A.G., Ohno K., Milone M., Wang H.-L., Nakano S., Bouzat C.,
RA   Pruitt J.N. II, Hutchinson D.O., Brengman J.M., Bren N., Sieb J.P.,
RA   Sine S.M.;
RT   "New mutations in acetylcholine receptor subunit genes reveal heterogeneity
RT   in the slow-channel congenital myasthenic syndrome.";
RL   Hum. Mol. Genet. 5:1217-1227(1996).
RN   [14]
RP   VARIANTS CMS1A SER-198; MET-201; ILE-299 AND ILE-314.
RX   PubMed=9158151; DOI=10.1093/hmg/6.5.767;
RA   Croxen R., Newland C., Beeson D., Oosterhuis H., Chauplannaz G.,
RA   Vincent A., Newsom-Davis J.;
RT   "Mutations in different functional domains of the human muscle
RT   acetylcholine receptor alpha subunit in patients with the slow-channel
RT   congenital myasthenic syndrome.";
RL   Hum. Mol. Genet. 6:767-774(1997).
RN   [15]
RP   VARIANT CMS1A PHE-294, AND CHARACTERIZATION OF VARIANT CMS1A PHE-294.
RX   PubMed=9221765; DOI=10.1523/jneurosci.17-15-05651.1997;
RA   Milone M., Wang H.-L., Ohno K., Fukudome T., Pruitt J.N. II, Bren N.,
RA   Sine S.M., Engel A.G.;
RT   "Slow-channel myasthenic syndrome caused by enhanced activation,
RT   desensitization, and agonist binding affinity attributable to mutation in
RT   the M2 domain of the acetylcholine receptor alpha subunit.";
RL   J. Neurosci. 17:5651-5665(1997).
RN   [16]
RP   VARIANTS CMS1B VAL-278 AND ILE-330, AND CHARACTERIZATION OF VARIANTS CMS1B
RP   VAL-278 AND ILE-330.
RX   PubMed=10195214; DOI=10.1038/6326;
RA   Wang H.-L., Milone M., Ohno K., Shen X.-M., Tsujino A., Batocchi A.-P.,
RA   Tonali P., Brengman J., Engel A.G., Sine S.M.;
RT   "Acetylcholine receptor M3 domain: stereochemical and volume contributions
RT   to channel gating.";
RL   Nat. Neurosci. 2:226-233(1999).
RN   [17]
RP   ERRATUM OF PUBMED:10195214.
RA   Wang H.-L., Milone M., Ohno K., Shen X.-M., Tsujino A., Batocchi A.-P.,
RA   Tonali P., Brengman J., Engel A.G., Sine S.M.;
RL   Nat. Neurosci. 2:485-485(1999).
RN   [18]
RP   VARIANT CMS1B LEU-177, AND CHARACTERIZATION OF VARIANT CMS1B LEU-177.
RX   PubMed=12588888; DOI=10.1172/jci200316997;
RA   Shen X.-M., Ohno K., Tsujino A., Brengman J.M., Gingold M., Sine S.M.,
RA   Engel A.G.;
RT   "Mutation causing severe myasthenia reveals functional asymmetry of AChR
RT   signature cystine loops in agonist binding and gating.";
RL   J. Clin. Invest. 111:497-505(2003).
RN   [19]
RP   VARIANT CMS1B LEU-301, AND CHARACTERIZATION OF VARIANT CMS1B LEU-301.
RX   PubMed=15079006; DOI=10.1212/01.wnl.0000118205.99701.41;
RA   Webster R., Brydson M., Croxen R., Newsom-Davis J., Vincent A., Beeson D.;
RT   "Mutation in the AChR ion channel gate underlies a fast channel congenital
RT   myasthenic syndrome.";
RL   Neurology 62:1090-1096(2004).
RN   [20]
RP   VARIANT CMS1A TRP-463, AND CHARACTERIZATION OF VARIANT CMS1A TRP-463.
RX   PubMed=16685696; DOI=10.1002/ana.20861;
RA   Shen X.-M., Deymeer F., Sine S.M., Engel A.G.;
RT   "Slow-channel mutation in acetylcholine receptor alphaM4 domain and its
RT   efficient knockdown.";
RL   Ann. Neurol. 60:128-136(2006).
RN   [21]
RP   VARIANT LMPS LEU-254.
RX   PubMed=18252226; DOI=10.1016/j.ajhg.2007.11.006;
RA   Michalk A., Stricker S., Becker J., Rupps R., Pantzar T., Miertus J.,
RA   Botta G., Naretto V.G., Janetzki C., Yaqoob N., Ott C.-E., Seelow D.,
RA   Wieczorek D., Fiebig B., Wirth B., Hoopmann M., Walther M., Koerber F.,
RA   Blankenburg M., Mundlos S., Heller R., Hoffmann K.;
RT   "Acetylcholine receptor pathway mutations explain various fetal akinesia
RT   deformation sequence disorders.";
RL   Am. J. Hum. Genet. 82:464-476(2008).
CC   -!- FUNCTION: After binding acetylcholine, the AChR responds by an
CC       extensive change in conformation that affects all subunits and leads to
CC       opening of an ion-conducting channel across the plasma membrane.
CC       {ECO:0000269|PubMed:27375219}.
CC   -!- SUBUNIT: Pentamer of two alpha chains, and one each of the beta, delta,
CC       and gamma (in immature muscle) or epsilon (in mature muscle) chains.
CC       The muscle heteropentamer composed of alpha-1, beta-1, delta, epsilon
CC       subunits interacts with the alpha-conotoxin ImII (PubMed:15609996).
CC       {ECO:0000269|PubMed:15609996}.
CC   -!- SUBCELLULAR LOCATION: Cell junction, synapse, postsynaptic cell
CC       membrane; Multi-pass membrane protein. Cell membrane; Multi-pass
CC       membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=2;
CC         IsoId=P02708-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=P02708-2; Sequence=VSP_000071;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is only expressed in skeletal muscle.
CC       Isoform 2 is constitutively expressed in skeletal muscle, brain, heart,
CC       kidney, liver, lung and thymus.
CC   -!- DISEASE: Multiple pterygium syndrome, lethal type (LMPS) [MIM:253290]:
CC       Multiple pterygia are found infrequently in children with
CC       arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal
CC       multiple pterygium syndrome there is intrauterine growth retardation,
CC       multiple pterygia, and flexion contractures causing severe
CC       arthrogryposis and fetal akinesia. Subcutaneous edema can be severe,
CC       causing fetal hydrops with cystic hygroma and lung hypoplasia.
CC       Oligohydramnios and facial anomalies are frequent.
CC       {ECO:0000269|PubMed:18252226}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=The alpha subunit is the main focus for antibody binding
CC       in myasthenia gravis. Myasthenia gravis is characterized by sporadic
CC       muscular fatigability and weakness, occurring chiefly in muscles
CC       innervated by cranial nerves, and characteristically improved by
CC       cholinesterase-inhibiting drugs.
CC   -!- DISEASE: Myasthenic syndrome, congenital, 1A, slow-channel (CMS1A)
CC       [MIM:601462]: A common congenital myasthenic syndrome. Congenital
CC       myasthenic syndromes are characterized by muscle weakness affecting the
CC       axial and limb muscles (with hypotonia in early-onset forms), the
CC       ocular muscles (leading to ptosis and ophthalmoplegia), and the facial
CC       and bulbar musculature (affecting sucking and swallowing, and leading
CC       to dysphonia). The symptoms fluctuate and worsen with physical effort.
CC       CMS1A is a slow-channel myasthenic syndrome. It is caused by kinetic
CC       abnormalities of the AChR, resulting in prolonged AChR channel opening
CC       episodes, prolonged endplate currents, and depolarization block. This
CC       is associated with calcium overload, which may contribute to subsequent
CC       degeneration of the endplate and postsynaptic membrane.
CC       {ECO:0000269|PubMed:16685696, ECO:0000269|PubMed:7619526,
CC       ECO:0000269|PubMed:8872460, ECO:0000269|PubMed:9158151,
CC       ECO:0000269|PubMed:9221765}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Myasthenic syndrome, congenital, 1B, fast-channel (CMS1B)
CC       [MIM:608930]: A form of congenital myasthenic syndrome, a group of
CC       disorders characterized by failure of neuromuscular transmission,
CC       including pre-synaptic, synaptic, and post-synaptic disorders that are
CC       not of autoimmune origin. Clinical features are easy fatigability and
CC       muscle weakness affecting the axial and limb muscles (with hypotonia in
CC       early-onset forms), the ocular muscles (leading to ptosis and
CC       ophthalmoplegia), and the facial and bulbar musculature (affecting
CC       sucking and swallowing, and leading to dysphonia). The symptoms
CC       fluctuate and worsen with physical effort. CMS1B is a fast-channel
CC       myasthenic syndrome. It is caused by kinetic abnormalities of the AChR,
CC       resulting in brief opening and activity of the channel, with a rapid
CC       decay in endplate current, failure to achieve threshold depolarization
CC       of the endplate and consequent failure to fire an action potential.
CC       {ECO:0000269|PubMed:10195214, ECO:0000269|PubMed:12588888,
CC       ECO:0000269|PubMed:15079006}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the ligand-gated ion channel (TC 1.A.9) family.
CC       Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha-1/CHRNA1 sub-
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA49705.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X02502; CAA26344.1; -; Genomic_DNA.
DR   EMBL; X02503; CAA26344.1; JOINED; Genomic_DNA.
DR   EMBL; X02504; CAA26344.1; JOINED; Genomic_DNA.
DR   EMBL; X02505; CAA26344.1; JOINED; Genomic_DNA.
DR   EMBL; X02506; CAA26344.1; JOINED; Genomic_DNA.
DR   EMBL; X02507; CAA26344.1; JOINED; Genomic_DNA.
DR   EMBL; X02508; CAA26344.1; JOINED; Genomic_DNA.
DR   EMBL; Y00762; CAA68731.1; -; mRNA.
DR   EMBL; X17104; CAA34960.1; -; Genomic_DNA.
DR   EMBL; AK299445; BAG61418.1; -; mRNA.
DR   EMBL; CH471058; EAX11125.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11127.1; -; Genomic_DNA.
DR   EMBL; S77094; AAD14247.1; -; mRNA.
DR   EMBL; X70108; CAA49705.1; ALT_FRAME; Genomic_DNA.
DR   CCDS; CCDS2261.1; -. [P02708-2]
DR   CCDS; CCDS33331.1; -. [P02708-1]
DR   PIR; A03168; ACHUA1.
DR   PIR; S10148; S10148.
DR   RefSeq; NP_000070.1; NM_000079.3. [P02708-2]
DR   RefSeq; NP_001034612.1; NM_001039523.2. [P02708-1]
DR   PDB; 1Y5P; Model; -; B=230-235.
DR   PDB; 1Y5T; Model; -; B=230-235.
DR   PDB; 1Y6C; Model; -; B=230-235.
DR   PDB; 4ZJS; X-ray; 2.23 A; A/B/C/D/E=21-50, A/B/C/D/E=106-126.
DR   PDB; 5HBT; X-ray; 2.61 A; B=21-256.
DR   PDBsum; 1Y5P; -.
DR   PDBsum; 1Y5T; -.
DR   PDBsum; 1Y6C; -.
DR   PDBsum; 4ZJS; -.
DR   PDBsum; 5HBT; -.
DR   SMR; P02708; -.
DR   BioGRID; 107556; 6.
DR   ComplexPortal; CPX-2179; Muscle-type nicotinic acetylcholine receptor complex, alpha1-beta1-delta-gamma.
DR   ComplexPortal; CPX-255; Muscle-type nicotinic acetylcholine receptor complex, alpha1-beta1-delta-epsilon.
DR   IntAct; P02708; 3.
DR   STRING; 9606.ENSP00000261007; -.
DR   BindingDB; P02708; -.
DR   ChEMBL; CHEMBL4808; -.
DR   DrugBank; DB08838; Agmatine.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugCentral; P02708; -.
DR   GuidetoPHARMACOLOGY; 462; -.
DR   TCDB; 1.A.9.1.1; the neurotransmitter receptor, cys loop, ligand-gated ion channel (lic) family.
DR   GlyGen; P02708; 1 site.
DR   iPTMnet; P02708; -.
DR   PhosphoSitePlus; P02708; -.
DR   BioMuta; CHRNA1; -.
DR   DMDM; 113071; -.
DR   MassIVE; P02708; -.
DR   PaxDb; P02708; -.
DR   PeptideAtlas; P02708; -.
DR   PRIDE; P02708; -.
DR   ProteomicsDB; 51554; -. [P02708-1]
DR   ProteomicsDB; 51555; -. [P02708-2]
DR   ABCD; P02708; 38 sequenced antibodies.
DR   Antibodypedia; 19487; 424 antibodies.
DR   DNASU; 1134; -.
DR   Ensembl; ENST00000261007; ENSP00000261007; ENSG00000138435. [P02708-1]
DR   Ensembl; ENST00000348749; ENSP00000261008; ENSG00000138435. [P02708-2]
DR   GeneID; 1134; -.
DR   KEGG; hsa:1134; -.
DR   UCSC; uc002ujd.3; human. [P02708-1]
DR   CTD; 1134; -.
DR   DisGeNET; 1134; -.
DR   GeneCards; CHRNA1; -.
DR   GeneReviews; CHRNA1; -.
DR   HGNC; HGNC:1955; CHRNA1.
DR   HPA; ENSG00000138435; Tissue enriched (skeletal).
DR   MalaCards; CHRNA1; -.
DR   MIM; 100690; gene.
DR   MIM; 253290; phenotype.
DR   MIM; 254200; phenotype.
DR   MIM; 601462; phenotype.
DR   MIM; 608930; phenotype.
DR   neXtProt; NX_P02708; -.
DR   OpenTargets; ENSG00000138435; -.
DR   Orphanet; 33108; Lethal multiple pterygium syndrome.
DR   Orphanet; 98913; Postsynaptic congenital myasthenic syndromes.
DR   PharmGKB; PA26487; -.
DR   VEuPathDB; HostDB:ENSG00000138435.14; -.
DR   eggNOG; KOG3645; Eukaryota.
DR   GeneTree; ENSGT00940000156851; -.
DR   HOGENOM; CLU_018074_1_0_1; -.
DR   InParanoid; P02708; -.
DR   OMA; STHIMPE; -.
DR   OrthoDB; 381858at2759; -.
DR   PhylomeDB; P02708; -.
DR   TreeFam; TF315605; -.
DR   PathwayCommons; P02708; -.
DR   Reactome; R-HSA-629594; Highly calcium permeable postsynaptic nicotinic acetylcholine receptors.
DR   Reactome; R-HSA-629597; Highly calcium permeable nicotinic acetylcholine receptors.
DR   SIGNOR; P02708; -.
DR   BioGRID-ORCS; 1134; 2 hits in 987 CRISPR screens.
DR   GeneWiki; Cholinergic_receptor,_nicotinic,_alpha_1; -.
DR   GenomeRNAi; 1134; -.
DR   Pharos; P02708; Tclin.
DR   PRO; PR:P02708; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P02708; protein.
DR   Bgee; ENSG00000138435; Expressed in quadriceps femoris and 102 other tissues.
DR   ExpressionAtlas; P02708; baseline and differential.
DR   Genevisible; P02708; HS.
DR   GO; GO:0005892; C:acetylcholine-gated channel complex; ISS:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0099060; C:integral component of postsynaptic specialization membrane; IEA:Ensembl.
DR   GO; GO:0031594; C:neuromuscular junction; IDA:MGI.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0045211; C:postsynaptic membrane; NAS:BHF-UCL.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0042166; F:acetylcholine binding; IEA:Ensembl.
DR   GO; GO:0015464; F:acetylcholine receptor activity; TAS:ProtInc.
DR   GO; GO:0022848; F:acetylcholine-gated cation-selective channel activity; IMP:MGI.
DR   GO; GO:0005216; F:ion channel activity; TAS:ProtInc.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:1904315; F:transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential; IDA:SynGO.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0034220; P:ion transmembrane transport; IBA:GO_Central.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IMP:BHF-UCL.
DR   GO; GO:0050881; P:musculoskeletal movement; IMP:BHF-UCL.
DR   GO; GO:0050877; P:nervous system process; IBA:GO_Central.
DR   GO; GO:0007528; P:neuromuscular junction development; IMP:MGI.
DR   GO; GO:0050905; P:neuromuscular process; IMP:BHF-UCL.
DR   GO; GO:0007274; P:neuromuscular synaptic transmission; IMP:MGI.
DR   GO; GO:0070050; P:neuron cellular homeostasis; IMP:BHF-UCL.
DR   GO; GO:0019228; P:neuronal action potential; IMP:BHF-UCL.
DR   GO; GO:0042391; P:regulation of membrane potential; IMP:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0003009; P:skeletal muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0048630; P:skeletal muscle tissue growth; IMP:BHF-UCL.
DR   Gene3D; 2.70.170.10; -; 1.
DR   InterPro; IPR006202; Neur_chan_lig-bd.
DR   InterPro; IPR036734; Neur_chan_lig-bd_sf.
DR   InterPro; IPR006201; Neur_channel.
DR   InterPro; IPR036719; Neuro-gated_channel_TM_sf.
DR   InterPro; IPR006029; Neurotrans-gated_channel_TM.
DR   InterPro; IPR018000; Neurotransmitter_ion_chnl_CS.
DR   InterPro; IPR002394; Nicotinic_acetylcholine_rcpt.
DR   PANTHER; PTHR18945; PTHR18945; 1.
DR   Pfam; PF02931; Neur_chan_LBD; 2.
DR   Pfam; PF02932; Neur_chan_memb; 2.
DR   PRINTS; PR00254; NICOTINICR.
DR   PRINTS; PR00252; NRIONCHANNEL.
DR   SUPFAM; SSF63712; SSF63712; 2.
DR   SUPFAM; SSF90112; SSF90112; 1.
DR   PROSITE; PS00236; NEUROTR_ION_CHANNEL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane;
KW   Congenital myasthenic syndrome; Direct protein sequencing; Disease variant;
KW   Disulfide bond; Glycoprotein; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Membrane; Postsynaptic cell membrane; Receptor;
KW   Reference proteome; Signal; Synapse; Transmembrane; Transmembrane helix;
KW   Transport.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000269|PubMed:2449458"
FT   CHAIN           21..482
FT                   /note="Acetylcholine receptor subunit alpha"
FT                   /id="PRO_0000000305"
FT   TOPO_DOM        21..255
FT                   /note="Extracellular"
FT   TRANSMEM        256..280
FT                   /note="Helical"
FT   TRANSMEM        288..306
FT                   /note="Helical"
FT   TRANSMEM        322..341
FT                   /note="Helical"
FT   TOPO_DOM        342..453
FT                   /note="Cytoplasmic"
FT   TRANSMEM        454..472
FT                   /note="Helical"
FT   CARBOHYD        186
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        173..187
FT   DISULFID        237..238
FT                   /note="Associated with receptor activation"
FT   VAR_SEQ         79..103
FT                   /note="Missing (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:3338555,
FT                   ECO:0000303|PubMed:7725386"
FT                   /id="VSP_000071"
FT   VARIANT         177
FT                   /note="V -> L (in CMS1B; mutant channel shows an
FT                   approximately 30-fold decrease of ACh binding affinity for
FT                   the second of 2 closed-state binding sites but only a 2-
FT                   fold decrease in gating efficiency; dbSNP:rs137852807)"
FT                   /evidence="ECO:0000269|PubMed:12588888"
FT                   /id="VAR_038599"
FT   VARIANT         198
FT                   /note="G -> S (in CMS1A; dbSNP:rs137852801)"
FT                   /evidence="ECO:0000269|PubMed:7619526,
FT                   ECO:0000269|PubMed:9158151"
FT                   /id="VAR_000282"
FT   VARIANT         201
FT                   /note="V -> M (in CMS1A; dbSNP:rs137852799)"
FT                   /evidence="ECO:0000269|PubMed:9158151"
FT                   /id="VAR_000283"
FT   VARIANT         254
FT                   /note="R -> L (in LMPS; dbSNP:rs137852809)"
FT                   /evidence="ECO:0000269|PubMed:18252226"
FT                   /id="VAR_043904"
FT   VARIANT         262
FT                   /note="N -> K (in CMS1A; dbSNP:rs137852798)"
FT                   /evidence="ECO:0000269|PubMed:8872460"
FT                   /id="VAR_000284"
FT   VARIANT         278
FT                   /note="F -> V (in CMS1B; markedly reduced protein
FT                   expression; dbSNP:rs137852805)"
FT                   /evidence="ECO:0000269|PubMed:10195214"
FT                   /id="VAR_021206"
FT   VARIANT         294
FT                   /note="V -> F (in CMS1A; causes increased channel opening
FT                   in absence of ACh; prolonged opening in presence of ACh;
FT                   increased affinity for ACh and enhanced desensitization;
FT                   dbSNP:rs137852803)"
FT                   /evidence="ECO:0000269|PubMed:9221765"
FT                   /id="VAR_021207"
FT   VARIANT         299
FT                   /note="T -> I (in CMS1A; dbSNP:rs137852800)"
FT                   /evidence="ECO:0000269|PubMed:9158151"
FT                   /id="VAR_000285"
FT   VARIANT         301
FT                   /note="F -> L (in CMS1B; fewer and shorter ion channel
FT                   activations with decreased channel opening rate and
FT                   increased channel closing rate; dbSNP:rs137852806)"
FT                   /evidence="ECO:0000269|PubMed:15079006"
FT                   /id="VAR_021208"
FT   VARIANT         314
FT                   /note="S -> I (in CMS1A; dbSNP:rs137852802)"
FT                   /evidence="ECO:0000269|PubMed:9158151"
FT                   /id="VAR_000286"
FT   VARIANT         330
FT                   /note="V -> I (in CMS1B; abnormally slow channel opening
FT                   and closing resulting in abnormally brief current;
FT                   dbSNP:rs137852804)"
FT                   /evidence="ECO:0000269|PubMed:10195214"
FT                   /id="VAR_021209"
FT   VARIANT         383
FT                   /note="D -> V (in dbSNP:rs6739001)"
FT                   /id="VAR_038600"
FT   VARIANT         463
FT                   /note="C -> W (in CMS1A; increases the rate of channel
FT                   opening and slows the rate of channel closing but has no
FT                   effect on agonist binding; dbSNP:rs137852808)"
FT                   /evidence="ECO:0000269|PubMed:16685696"
FT                   /id="VAR_038601"
FT   MUTAGEN         300
FT                   /note="V->A: Increased length of channel opening."
FT                   /evidence="ECO:0000269|PubMed:27375219"
FT   CONFLICT        415
FT                   /note="P -> F (in Ref. 4; AAD14247)"
FT                   /evidence="ECO:0000305"
FT   HELIX           23..31
FT                   /evidence="ECO:0007744|PDB:4ZJS"
FT   STRAND          37..39
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          49..52
FT                   /evidence="ECO:0007744|PDB:4ZJS"
FT   TURN            65..68
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          69..78
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          106..111
FT                   /evidence="ECO:0007744|PDB:4ZJS"
FT   HELIX           114..117
FT                   /evidence="ECO:0007744|PDB:4ZJS"
FT   STRAND          122..126
FT                   /evidence="ECO:0007744|PDB:4ZJS"
FT   HELIX           127..129
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          135..138
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          140..145
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          152..156
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          159..163
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          166..172
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          184..195
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   TURN            198..200
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          201..209
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          219..235
FT                   /evidence="ECO:0007744|PDB:5HBT"
FT   STRAND          243..254
FT                   /evidence="ECO:0007744|PDB:5HBT"
SQ   SEQUENCE   482 AA;  54546 MW;  8B307AD69B91A28B CRC64;
     MEPWPLLLLF SLCSAGLVLG SEHETRLVAK LFKDYSSVVR PVEDHRQVVE VTVGLQLIQL
     INVDEVNQIV TTNVRLKQGD MVDLPRPSCV TLGVPLFSHL QNEQWVDYNL KWNPDDYGGV
     KKIHIPSEKI WRPDLVLYNN ADGDFAIVKF TKVLLQYTGH ITWTPPAIFK SYCEIIVTHF
     PFDEQNCSMK LGTWTYDGSV VAINPESDQP DLSNFMESGE WVIKESRGWK HSVTYSCCPD
     TPYLDITYHF VMQRLPLYFI VNVIIPCLLF SFLTGLVFYL PTDSGEKMTL SISVLLSLTV
     FLLVIVELIP STSSAVPLIG KYMLFTMVFV IASIIITVIV INTHHRSPST HVMPNWVRKV
     FIDTIPNIMF FSTMKRPSRE KQDKKIFTED IDISDISGKP GPPPMGFHSP LIKHPEVKSA
     IEGIKYIAET MKSDQESNNA AAEWKYVAMV MDHILLGVFM LVCIIGTLAV FAGRLIELNQ
     QG
//
